BioAdvance is an evergreen fund established to address the critical needs of emerging human life science focused companies. Committed to fueling innovation, BioAdvance supports companies dedicated to developing technologies that can meaningfully impact human health. This support has empowered innovators to advance groundbreaking health technologies and expand access to subsequent funding through venture capital, grants, collaborations, and mergers and acquisitions.
WHAT WE INVEST IN COMPANIES DEVELOPING
- Therapeutics
- Medical Devices
- Digital Health
- Diagnostics
- Research Tools
115
Companies invested in
23
Exits in all sectors
12
Products with FDA approval
Empowering Health Innovation
OUR APPROACH
BioAdvance takes a mission-driven approach by providing crucial early-stage funding to life sciences companies, empowering them to develop transformative health technologies and attract substantial follow-on investments.
An Experienced Team
Business executives. Scientists. Physicians. Entrepreneurs. Our team consists of people with deep industry experience.
We’re Collaborative
We understand what it takes for companies to grow and we work closely with our entrepreneurs to help them succeed.
Capital Efficiency is Key
We understand and help our companies maximize the value of scarce capital.
We Invest For Financial Return
We’re an evergreen fund that continues to grow and invest.
Focus On Human Health
We invest in technologies that have the potential to improve human health.
Our Companies are Successful
Our portfolio has attracted over $4.2B in follow-on funding.
What We Look For
Geography
We focus on investments in companies headquartered in the Mid-Atlantic U.S., specifically along the I-95 corridor between New York City and Washington, D.C. We also require the CEO to be based in this region, ensuring strong leadership presence within our geographic focus.
Sector
Our investments are dedicated to advancing human health with a core focus on therapeutic innovations. We also look for opportunities in medical devices, digital health, diagnostics, and research tools that address significant unmet needs in healthcare.
Stage of Investment
Our primary interest lies in seed and Series A opportunities. We aim to provide funding that enables companies to reach critical de-risking or value-inflection points—milestones that significantly enhance their appeal to larger venture capital firms, corporate partners, or other funding sources, including product revenue.
For digital health investments, we look for companies with proven product-market-fit and established market traction as demonstrated by a growing revenue stream.
Investment Size
Our investment philosophy is centered on strategic, impactful capital that drives companies to critical milestones. Our initial investment size typically ranges from $500,000 to $1,500,000, and we have the ability to commit up to $5 million over the lifecycle of a company. While we are open to participating in funding rounds of any size, our focus is on supporting early-stage ventures on the path to significant value creation. We would consider leading rounds between $500,000 and $5 million, bringing expertise and capital to accelerate product development, market validation, and growth initiatives. Our goal is to position companies for success in future fundraising rounds, enabling them to capture their market potential and scale effectively.